Cargando…
Palliative care and end of life management in patients with idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic disease with an unknown etiology that causes deterioration of the structure of the lung parenchyma, resulting in a severe and progressive decline in respiratory function and early mortality. IPF is essentially an incurable disease, with a mean overall...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications, Pavia, Italy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9994447/ https://www.ncbi.nlm.nih.gov/pubmed/36909932 http://dx.doi.org/10.4081/mrm.2023.896 |
_version_ | 1784902634823483392 |
---|---|
author | Micco, Assunta Carpentieri, Emanuela Di Sorbo, Antonio Chetta, Alfredo Del Donno, Mario |
author_facet | Micco, Assunta Carpentieri, Emanuela Di Sorbo, Antonio Chetta, Alfredo Del Donno, Mario |
author_sort | Micco, Assunta |
collection | PubMed |
description | Idiopathic pulmonary fibrosis (IPF) is a chronic disease with an unknown etiology that causes deterioration of the structure of the lung parenchyma, resulting in a severe and progressive decline in respiratory function and early mortality. IPF is essentially an incurable disease, with a mean overall survival of 5 years in approximately 20% of patients without treatment. The combination of a poor prognosis, uncertainty about the disease's progression, and the severity of symptoms has a significant impact on the quality of life of patients and their families. New antifibrotic drugs have been shown to slow disease progression, but their impact on health-related quality of life (HRQoL) has to be proven yet. To date, studies have shown that palliative care can improve symptom management, HRQoL, and end-of-life care (EoL) in patients with IPF, reducing critical events, hospitalization, and health costs. As a result, it is essential for proper health planning and patient management to establish palliative care early and in conjunction with other therapies, beginning with the initial diagnosis of the disease. |
format | Online Article Text |
id | pubmed-9994447 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | PAGEPress Publications, Pavia, Italy |
record_format | MEDLINE/PubMed |
spelling | pubmed-99944472023-03-09 Palliative care and end of life management in patients with idiopathic pulmonary fibrosis Micco, Assunta Carpentieri, Emanuela Di Sorbo, Antonio Chetta, Alfredo Del Donno, Mario Multidiscip Respir Med Review Idiopathic pulmonary fibrosis (IPF) is a chronic disease with an unknown etiology that causes deterioration of the structure of the lung parenchyma, resulting in a severe and progressive decline in respiratory function and early mortality. IPF is essentially an incurable disease, with a mean overall survival of 5 years in approximately 20% of patients without treatment. The combination of a poor prognosis, uncertainty about the disease's progression, and the severity of symptoms has a significant impact on the quality of life of patients and their families. New antifibrotic drugs have been shown to slow disease progression, but their impact on health-related quality of life (HRQoL) has to be proven yet. To date, studies have shown that palliative care can improve symptom management, HRQoL, and end-of-life care (EoL) in patients with IPF, reducing critical events, hospitalization, and health costs. As a result, it is essential for proper health planning and patient management to establish palliative care early and in conjunction with other therapies, beginning with the initial diagnosis of the disease. PAGEPress Publications, Pavia, Italy 2023-02-21 /pmc/articles/PMC9994447/ /pubmed/36909932 http://dx.doi.org/10.4081/mrm.2023.896 Text en ©Copyright: the Author(s) https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Review Micco, Assunta Carpentieri, Emanuela Di Sorbo, Antonio Chetta, Alfredo Del Donno, Mario Palliative care and end of life management in patients with idiopathic pulmonary fibrosis |
title | Palliative care and end of life management in patients with idiopathic pulmonary fibrosis |
title_full | Palliative care and end of life management in patients with idiopathic pulmonary fibrosis |
title_fullStr | Palliative care and end of life management in patients with idiopathic pulmonary fibrosis |
title_full_unstemmed | Palliative care and end of life management in patients with idiopathic pulmonary fibrosis |
title_short | Palliative care and end of life management in patients with idiopathic pulmonary fibrosis |
title_sort | palliative care and end of life management in patients with idiopathic pulmonary fibrosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9994447/ https://www.ncbi.nlm.nih.gov/pubmed/36909932 http://dx.doi.org/10.4081/mrm.2023.896 |
work_keys_str_mv | AT miccoassunta palliativecareandendoflifemanagementinpatientswithidiopathicpulmonaryfibrosis AT carpentieriemanuela palliativecareandendoflifemanagementinpatientswithidiopathicpulmonaryfibrosis AT disorboantonio palliativecareandendoflifemanagementinpatientswithidiopathicpulmonaryfibrosis AT chettaalfredo palliativecareandendoflifemanagementinpatientswithidiopathicpulmonaryfibrosis AT deldonnomario palliativecareandendoflifemanagementinpatientswithidiopathicpulmonaryfibrosis |